M Yildirim, B Karabulut
M Yildirim, B Karabulut. Hand- Foot Syndrome And Cutaneous Reactıons Followıng Fırst Dose Of Chemotherapy. The Internet Journal of Oncology. 2009 Volume 7 Number 1.
A 63-year-old female with stage IIIA breast cancer was treated in our department with adjuan chemotherapy containing 5- fluoruracil,epirubicine and cyclophosphamide. Clinical and anamnetic findings revealed no signs of any disorder and physical examination was unremarkable. The patient received, 5- fluoruracil 720 mg/m 2 , epirubicine 145mg/m2 and cyclophosphamide 720 mg/m2 administered as a infusion on day one, repeated every three weeks. Treatment given on day 1 was preceded by dexametasone 4 mg i.v. and granisetron 3 mg i.v. for the prophylaxis of nausea and vomiting. The same anti-emetic treatment was repeated i.v.on day 2 and orally on days 3 and 4. The first treatment cycle was uneventful. Four days after administration of the second cycle the patient was admitted to our clinic with hand-foot syndrome(HFS), associated with nail changes on hand (hyperpigmentation) and maculopapuler eruptions on the trunk(Figure 1,2,3,4 and 5).
In our case, HFS was associated cutaneous reactions which progress to the body of the patient. After the first episode of HFS, interruption of therapy was necessary.The patient was used pyridoxine with dose of 100mg /d.and local thearpy with cooling hand and foot baths. Chemotherapy was restarted according to the original scheme after 2 weeks.
Palmar-Plantar Erythrodysesthesia, also called hand-foot syndrome is a side-effect of chemotherapy or biologic drugs used to treat cancer. It results following administration of chemotherapy leak out of small amounts of drug from capillaries in the palms of the hands and soles of the feet. Exposure of the hands and feet to heat or friction increases the drug leakage from the capillaries. This leakage of drug results in redness, tenderness, peeling and numbness. HFS occurs most frequently in therapy with 5-Fluoruracil (5-FU), capecitabine ,vinorelbin, continuous-infusion doxorubicin, docetaxel and high-dose Interleukin-2. There is no evidence in the literature that HFS prefers a race or population group.